Clinical trial
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
NCT00487682 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00487682 |
|---|---|
| Title | Dose-finding Study of ASP2151 in Subjects With Herpes Zoster |
| Official title | Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter, Randomized, Double-blind, Valacyclovir Hydrochloride-controlled, Parallel-group, Comparative Study |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Herpes Zoster |
| Intervention type | Drug |
| Interventions | ASP2151, Valacyclovir hydrochloride |
| Enrollment | 403 |
| Start date | Nov 13, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jun 18, 2007 |
| Last update posted | Nov 23, 2018 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: